eResearch analysts, Beverly Brooks, MA (Economics), MBA and Bob Leshchyshen, BA, MBA, CFA, have written an Initiating Report on Cannasat Therapeutics
eResearch analysts, Beverly Brooks, MA (Economics), MBA and Bob Leshchyshen, BA, MBA, CFA, have written an Initiating Report on Cannasat Therapeutics Inc. (TSX VENTURE:CTH). Cannasat is a specialty pharmaceutical company focused on developing a portfolio of cannabinoid-based pharmaceutical products.
In the Report, the Analysts state: “Cannasat has a substantially lower risk and lower cost product development strategy as compared to the other innovative, early-stage pharmaceutical/biotechnology companies since it is initially focusing on molecules that are already marketed and are known to be effective. If Cannasat successfully completes formulation development and early-stage clinical testing for its products in the pipeline, it should be able to sign marketing and co-development deals with larger pharmaceutical companies.”
eResearch is Canada’s primary source for independent, quality, investment research, focused primarily on small- and mid-cap companies. Our research and analysis is of institutional quality, and has the potential of reaching millions of global investors through our extensive Internet distribution network. eResearch does not trade in the securities of the companies it covers, nor does it accept any stock related compensation for research services. eResearch does not engage in retail or institutional sales, trading, or corporate finance activities, nor does it conduct investment banking or investor relations services for the companies covered. Our sole business is providing quality, unbiased research.
Cannasat Therapeutics Inc. paid eResearch a fee of C$17,000 + GST to conduct research on the Company, on an Annual Continuous Coverage basis.
Cannasat Therapeutics Inc.
Vice President, Operations
(416) 703-2449 Ext. 253
(416) 703-8752 (FAX)
Email: [email protected] or [email protected]
Bob Weir, CFA, Director of Research
Email: [email protected]